VIPhyb

VIPhyb is a first-generation peptide-based antagonist of the vasoactive intestinal peptide (VIP) receptors, VPAC1 and VPAC2. It was designed as a hybrid peptide consisting of the six charged N-terminal residues of neurotensin fused to the C-terminal amino acid sequence of VIP. By blocking VIP signaling, which is naturally immunosuppressive, VIPhyb enhances T-cell activation, proliferation, and anti-tumor immunity. It has been studied primarily in preclinical models of hematologic malignancies, such as acute myeloid leukemia (AML) and T-cell lymphoblastic leukemia, where it has demonstrated the ability to improve T-cell dependent anti-tumor responses. While VIPhyb served as a proof-of-concept for VIP receptor inhibition in oncology, second-generation antagonists (such as ANT308 and ANT195) have since been developed with higher binding affinities and superior in vivo potency.

Other names

VIP-hybridNeurotensin-VIP hybrid peptide